"No patient with peripheral T-cell lymphoma is left behind."

In 2023, Salvia Jain, MD, a hematologist-oncologist at Massachusetts General Hospital, recognized the lack of systematic, multimodal longitudinal data for patients with peripheral T-cell lymphoma (PTCL). In response, she founded PETAL Consortium—a first-of-its-kind global network dedicated to advancing care for this rare and aggressive blood cancer by serving as a central hub of information.
PTCL’s rarity has significantly impeded research efforts and clinical trial development in a reasonable timeframe. PETAL overcomes this challenge by uniting leading centers of excellence in PTCL clinical care and research worldwide, enabling investigators to generate, collate, and access data from hundreds of patients.
Today, PETAL brings together more than 100 investigators from over 20 international research sites–spanning lymphoma medicine, artificial intelligence, systems biology, pathology, genomics, biostatistics, and bioinformatics–to accelerate discovery and transform how PTCL is understood and treated.